Spotlight on New Antibiotics for the Treatment of Pneumonia
1Division of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Abstract:
In the last years, the presence of multidrug-resistant (MDR) Gram-negative (like Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii) and Gram-positive bacteria (mostly methicillin-resistant Staphylococcus aureus) was worldwide reported, limiting the options for an effective antibiotic therapy. For these reasons, inappropriate antimicrobial therapy and delayed prescription can lead to an unfavorable outcome, especially in patients with pneumonia. New antibiotics approved belong to classes of antimicrobials, like beta-lactams with or without beta-lactamase inhibitors, aminoglycosides, oxazolidinones, quinolones, and tetracyclines, or based on new mechanisms of action. These new compounds show many advantages, including a broad spectrum of activity against MDR pathogens, good lung penetration, safety and tolerability, and finally the possibility of intravenous and/or oral formulations. However, the new antibiotics under development represent an important possible armamentarium against difficult-to-treat strains. The safety and clinical efficacy of these future drugs should be tested in clinical practice. In this review, there are reported characteristics of newly approved antibiotics that represent potential future options for the treatment of respiratory tract infections, including those caused by multidrug-resistant bacteria. Finally, the characteristics of the drugs under development are briefly reported.
Insights
New antibiotics offer hope against multidrug-resistant bacteria, including those causing pneumonia. This review covers recently approved drugs and those in development for treating challenging respiratory tract infections.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Rising global prevalence of multidrug-resistant (MDR) Gram-negative (e.g., *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Acinetobacter baumannii*) and Gram-positive bacteria (e.g., methicillin-resistant *Staphylococcus aureus*).
- Limited effective antibiotic therapy options due to antimicrobial resistance.
- Inappropriate antimicrobial therapy and delayed prescriptions contribute to poor outcomes, particularly in pneumonia cases.
Purpose of the Study:
- To review newly approved antibiotics for treating respiratory tract infections (RTIs), including those caused by MDR pathogens.
- To briefly report on the characteristics of antibiotics currently under development.
- To highlight potential future therapeutic options against difficult-to-treat bacterial strains.
Main Methods:
- Literature review of recently approved antimicrobial agents.
- Analysis of drug classes including beta-lactams, aminoglycosides, oxazolidinones, quinolones, and tetracyclines.
- Brief overview of novel antibiotics in the development pipeline.
Main Results:
- Newly approved antibiotics offer broad-spectrum activity against MDR pathogens.
- These agents demonstrate favorable characteristics such as good lung penetration, safety, tolerability, and flexible administration routes (IV/oral).
- Emerging antibiotics in development represent a crucial future armamentarium against resistant infections.
Conclusions:
- Newly approved antibiotics provide valuable options for managing RTIs, especially those involving MDR bacteria.
- Antibiotics in development require further clinical evaluation for safety and efficacy.
- These advancements are critical in combating the growing threat of antimicrobial resistance.
More Related Videos
03:22Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
07:46Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:30Pneumonia III: Complications and Assessment
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...